Home » Stocks » OLMA

Olema Pharmaceuticals, Inc. (OLMA)

Stock Price: $37.66 USD 1.25 (3.43%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 1.53B
Revenue (ttm) n/a
Net Income (ttm) -14.88M
Shares Out 38.52M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $37.66
Previous Close $36.41
Change ($) 1.25
Change (%) 3.43%
Day's Open 37.01
Day's Range 32.12 - 38.52
Day's Volume 180,285
52-Week Range 32.11 - 60.27

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, d...

Invezz - 2 months ago

The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sus...

Other stocks mentioned: MORF, SDGR
GlobeNewsWire - 2 months ago

SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and...

GuruFocus - 3 months ago

Since going public on Nov. 19, shares of Olema Pharmaceuticals Inc.(NASDAQ:OLMA) have soared past the offering price of $19 per share to over $53, giving the San Francisco-based company a mark...

GlobeNewsWire - 3 months ago

SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and...

GlobeNewsWire - 3 months ago

SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and...

About OLMA

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Ole... [Read more...]

Industry
Biotechnology
IPO Date
Nov 19, 2020
Stock Exchange
NASDAQ
Ticker Symbol
OLMA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for OLMA is 60.67, which is an increase of 61.10% from the latest price.

Price Target
$60.67
(61.10% upside)